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To the Editor:
We read with interest the article by
Santarpino and colleagues1 in which
they compared minimally invasive
aortic valve replacement with suture-
less valves with transcatheter aortic
valve implantation in a propensity-
matched cohort of 37 patients in
each group. They concluded that the
advantages of sutureless valves are
shorter procedural times (crossclamp
time of 38.9  13.7 minutes and car-
diopulmonary bypass time of 68.9 
20.2 minutes) and less paravalvular
leak relative to transcatheter aortic
valve implantation. They reported
a high incidence of permanent
pacemaker implantation (10.8%).
The incidence of paravalvular leak
with sutureless valves in the literature
varies from 2% to 15%.2,3 Santarpino
and colleagues attributed their low
paravalvular leak to ‘‘moderate
decalcification.’’
To produce superior results to trans-
catheter aortic valve implantation in
high-risk patients, first, zero paravalvu-
lar leak with fairly large prosthesis size
and effective orifice area and low pace-
maker implantation rate are required.
These conditions will not be met by364 The Journal of Thoracic and Cmoderate or even less decalcification
of the annulus. Second, cardiopulmo-
nary bypass is the key contraindication
to surgery for elderly patients, particu-
larly those with pulmonary dysfunc-
tion, not the duration of bypass and
clamp time. The bypass and clamp
times achieved by Santarpino and
colleagues1 with sutureless valves are
not too different from our own
propensity-matched series4 of 205 pa-
tients (crossclamp time of 49 minutes
with a range of 42-63 minutes and car-
diopulmonary bypass time of 71 mi-
nutes with a range of 59-94 minutes)
in which we used minimally invasive
incision but with valve sutures. Even
in reoperative minimal access aortic
valve replacement (with or without
concomitant procedures)with standard
suturing techniques, fairly short cross-
clamp times can be achieved.5
Very good applications of suture-
less valves would be for a patient
with a failing homograft with a
severely calcified annulus and also
for difficult reoperations when the
annulus has been destroyed.
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To the Editor:
We wish to thank Dr Soppa for his
comments on our study published in
the February issue of the Journal.1
His contribution helps to keep alive
the debate on the most appropriate
treatment strategy for high-risk
patients with severe aortic stenosis.
We acknowledge that our study had
several limitations, as was stated in
the discussion, including a lack of
randomization and failure to consider
relevant factors such as patient frailty.
The main advantage of sutureless
aortic valve replacement versus trans-
catheter aortic valve implantation is
the lower or nil rate of paravalvular
leak, which has also been confirmed
by other investigators,2 and not
a shorter cardiopulmonary bypass
time, such as suggested by Dr Soppa.
This finding is of particular relevance
given the well-recognized correlation
between even mild paravalvular
leakage and increased mortality
during follow-up.3 We congratulate
Soppa and colleagues for the results
they presented at the last Society
for Cardiothoracic Surgery Congress
showing similar aortic crossclamp
times in minimally invasive surgery
using a stented prosthesis. Recently,
we demonstrated that in patients
undergoing isolated aortic valve
replacement, the aortic crossclamp
times were reduced by 40% when a
minimally invasive approach was
Letters to the Editorperformed.4 Soppa and colleagues
might, therefore, achieve even better
surgical results using the sutureless
technique with significant improve-
ment in patient outcomes.5
We fully agree with Dr Soppa that
sutureless aortic valve replacement is
an ideal option for redo surgery,
such as was recently suggested by
our preliminary data in this patient
subset.6
We believe that sutureless aortic
valve prostheses have the potential to
shorten the surgical time, and future
research will determine whether this
advantage will also translate into
better outcomes in high-risk patients.
Sutureless aortic valve replacement
has been shown to be associated with
improved survival compared with
transcatheter aortic valve implanta-
tion, owing to the lower or no
rates of residual aortic regurgitation.
Only randomized prospective studies
comparing the 2 surgical techniques
will allow definite conclusions to be
drawn regarding this issue.
Giuseppe Santarpino, MD
Francesco Pollari, MD
Theodor Fischlein, MD
Department of Cardiac Surgery
Klinikum Nuremberg
Nuremberg, Germany
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With all due respect to the clinical
competence of Drs Delaere and Van
Raemdonck, we would like to address
their pointed critique as not only un-
substantiated but also demonstrably
false, which is both disturbing and
damaging to the field of tracheal
transplantation.1
The most disturbing comment is
‘‘more than half of the patients died
within a 3-month period.’’1 This is
incorrect. Of our first 9 clinical appli-
cations using a natural scaffold, only 1
died within the short-term period, and
the death was unrelated to the trans-
plantation. A report detailing these
cases is under review for publication.
We can firmly suggest tissue-
engineered tracheal replacement is
not ‘‘destined to fail’’ as evidenced
by survivors beyond 67 months.2
Second, the editorial states
‘‘Tracheal bioengineering was not
tested in animal models,’’ which is un-
true, based on our previous publica-
tions. In fact, in 1994, we described
the surgical technique for, and revas-
cularization of, tracheal allotransplan-
tations in pigs, published in this
Journal.3 To avoid immunosuppres-
sion, several large and small animal
models and in vitro airway transplan-
tation studies, not requiring immuno-
suppression were then completed and
published in peer-reviewed journals
(the number exceeded the reference
limit). All have supported the readi-
ness for ethical clinical application.
Additionally, advances in neoangio-
genesis, epithelial differentiation,
stem cell biology, and systemic and
in situ regenerative processes have
been reported.4,5 From this sound
preclinical evidence, human airwayof Thoracic and Cardiovascular Surgetransplantation has been approved by
national and local regulatory bodies
in 6 countries, including the US
Food and Drug Administration,
widely regarded as the world’s
toughest regulatory body.
Finally, Delaere and Van Raem-
donck suggested ‘‘dissemination of
misinformation’’ could be avoided
with ‘‘clear visualization of the tra-
chea.’’ Video endoscopy, high-
resolution computed tomography
scan images, and photomicrography
of the regenerated respiratory epithe-
lium, 5 years after transplantation
and without an airway stent in place
have, in fact, been published,2 and
whose evidence cannot be disputed.
We value the comments of Delaere
and Van Raemdonck and other leaders
in this field. We do not expect undis-
puted acceptance of our approach;
however, we would appreciate a
certain degree of collegiality and
respect for our unceasing efforts to
push for an innovative and scientifi-
cally sound solution for a vexing clin-
ical problem. The trachea is ‘‘one of
the most difficult organs in the human
body to replace.’’ Rebuilding an iden-
tical copy of the native airway might
not be possible; however, creating an
ideal, nonimmunogenic replacement
is. The best strategy for replacement
and regeneration has yet to be deter-
mined. Tissue-engineered tracheal
transplantation is still in its experi-
mental phase, far from routine clinical
application, and awaits the results of
an ongoing clinical trial (www.
clinicaltrials.gov). However, the as-
sertions that our preclinical and
translational advances in tracheal
transplantation are ‘‘misleading and
unrealistic’’ are overreaching, given
the extensive published data support-
ing the cells-to-bioartificial scaffold
interactions and documented long-
term survival of our own patient
series.
Finally, the editorial questions
whether the trachea is really the first
bioengineered organ. This claim has
never been made by us, but rather inry c Volume 148, Number 1 365
